Day: December 11, 2022

–   89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up –   Rapid and deep responses seen including first confirmed CR at 20 weeks; 77% of patients with at least 2 cycles of treatment had complete clearance of bone marrow mast cell aggregates –   Favorable safety and tolerability profile with no related cognitive effects or reported intracranial bleeding events –   Cogent to host investor webcast Monday, December 12 at 8:00 a.m. ET  WALTHAM, Mass. and BOULDER, Colo., Dec. 11, 2022 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive updated clinical data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT...

Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune systems Allogeneic HIP CAR T cells can be produced with novel gene editing platform CRISPR/Cas12b at large scale and high gene-editing efficiency HIP-modified allogeneic BCMA-targeted CAR T cells demonstrate in vitro efficacy and cytokine production against BCMA+ target cells against multiple myeloma Fusosomes specifically transduce primary, non-activated CD8+ T cells to generate highly functional CAR T cells capable of eliminating CD19+ tumor cells in animal models with two dosing strategies SEATTLE, Dec. 11, 2022 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells...

Media Release COPENHAGEN, Denmark; December 11, 2022Epcoritamab featured in multiple data disclosures, including four oral presentations Results presented from the phase 1b/2 EPCORE™ NHL-2 trial of epcoritamab combined with standard salvage therapy in patients with transplant eligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Additional results also presented from the phase 1b/2 EPCORE NHL-2 trial evaluating epcoritamab combined with existing therapies in patients with R/R follicular lymphoma (FL) and previously untreated FL Results presented from phase 1b/2 EPCORE CLL-1 trial evaluating epcoritamab in patients with Richter’s Syndrome (RS) Additional results also presented from the phase 1/2 EPCORE NHL-1 trial, evaluating epcoritamab in patients with R/R large B-cell lymphoma (LBCL)Genmab A/S (Nasdaq: GMAB)...

Figure 1 2022/2023 Drilling Programme and TargetsHighlightsDrill rig mobilized quickly to site to begin dry season drill campaign The 2022/2023 exploration drilling programme is focusing on targeting highly prospective areas, specifically around strike extensionTORONTO, Dec. 11, 2022 (GLOBE NEWSWIRE) — Toubani Resources, Inc. (ASX: TRE; TSX-V: TRE) (“Toubani Resources” or the “Company”) is pleased to announce that a 10,750 meter drill program has commenced at the Company’s flagship Kobada Gold Project in southern Mali. The 2022/2023 drilling campaign is designed to focus on targeting highly prospective strike extension from the existing resource base. The 10,750 meters drill program will mark the first drilling campaign following the dual listing on the Australian Securities Exchange (“ASX”) and will focus on the previously...

Norsk Hydro’s Annual Report 2021 on European Single Electronic Format (ESEF) was published accessible through Norsk Hydro’s website on November 17, 2022. Following requirements, the report is also published through Oslo Stock Exchange. For any questions, please contact: Line Haugetraa+4741406376line.haugetraa@hydro.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachment549300N1SDN71ZZ8BO45-2021-12-31-en

  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE “TAKEOVER RULES”). THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION. Statement from Sanofi regarding Horizon Therapeutics plc (“Horizon”) Paris, December 11, 2022. Sanofi S.A. (“Sanofi”) regularly evaluates a wide variety of business development opportunities and this has included the evaluation of a possible transaction involving Horizon. As transaction price expectations do not meet our value creation criteria, Sanofi announces it is no longer in discussions with Horizon and it does not intend to make an offer for Horizon.This announcement...

Artemis Prime Industry Team Congratulates NASA on Success of Artemis I WASHINGTON, Dec. 11, 2022 (GLOBE NEWSWIRE) — NASA’s Artemis I mission came to a successful conclusion today with the splashdown and recovery of the Orion spacecraft. This mission was an uncrewed, integrated flight test of the hardware and technology that will take humans back to the Moon for the first time in more than five decades. The Space Launch System (SLS) rocket, Orion spacecraft and Exploration Ground Systems (EGS) at NASA’s Kennedy Space Center in Florida performed flawlessly during the Artemis I launch on Nov. 16. During a nearly 26-day mission, Orion traveled more than 1.4 million miles on a path that took it around and beyond the Moon before returning to Earth. The flight testing and data from the mission inform future Artemis missions. As the foundational...

RVU120 Demonstrates Single-Agent Activity with a Complete Response, 4 Blast Reductions, and 4 Erythroid and/or Platelet responses in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS);Preclinical Antitumor Activity of SEL24 (MEN1703) demonstrated in multiple myeloma (MM), Hodgkin’s lymphoma (HL), and diffuse large B-cell lymphoma (DLBCL) as well as in AML in combination with gilteritinib;Company to Host Investor Webinar on December 12 at 8 am CET (1 pm CT) to Review Data Presented. To register for the event, please click here.KRAKOW, Poland, Dec. 11, 2022 (GLOBE NEWSWIRE) — Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced new data...

First Preclinical Data for IGM-2644 and IGM-2537 Featured in Poster Presentations MOUNTAIN VIEW, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced the presentation of data from IGM’s expanding portfolio of T cell engagers for hematologic malignancies, including IGM-2644, IGM-2537 and imvotamab, at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition being held virtually and in-person in New Orleans, Louisiana, December 10-13, 2022. “As shown today, the preclinical profiles of IGM-2644, our CD38 x CD3 bispecific IgM antibody, and IGM-2537, our CD123 x CD3 bispecific IgM antibody, demonstrate the potential for encouraging antitumor activity coupled with favorable safety profiles,”...

Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated AML Additional presentations highlight Kronos Bio’s collaboration with academic cooperative groups to better understand the predictive value of measurable residual disease SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 11, 2022 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, is presenting preclinical data that demonstrate anti-leukemic activity of the investigational spleen tyrosine kinase (SYK) inhibitor, lanraplenib, in combination with multiple targeted agents in patient-derived cell isolates and cell lines at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition in New Orleans. The data are...